Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa

Krishna P. Reddy, MD[1,2,3]

Fatma M. Shebl, PhD[1,3]

Julia H. A. Foote, BA[1]

Guy Harling, ScD[4,5,6,7]

Justine A. Scott, MPH[1]

Christopher Panella, BA[1]

Clare Flanagan, MPH[1]

Emily P. Hyle, MD[1,3,8,9]

Anne M. Neilan, MD[1,3,8,10]

Amir M. Mohareb, MD[1,3,8]

Prof. Linda-Gail Bekker, MBChB[11]

Richard J. Lessells, PhD[12]

Andrea L. Ciaranello, MD[1,3,8,9]

Prof. Robin Wood, DSc[11]

Prof. Elena Losina, PhD[3,13,14,15]

Prof. Kenneth A. Freedberg, MD[1,3,8,16,17]

Pooyan Kazemian, PhD[1,3]*

Mark J. Siedner, MD[1,3,5,8]*

* PK and MJS contributed equally to this work.

Affiliations

[1] Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA

[2] Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA

[3] Harvard Medical School, Boston, MA, USA

[4] Department of Epidemiology and Harvard Center for Population & Development Studies, Harvard T.H. Chan School of Public Health, Boston, MA, USA

[5] Africa Health Research Institute, KwaZulu-Natal, South Africa

[6] Institute for Global Health, University College London, London, UK

[7] MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of Witwatersrand, South Africa

[8] Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

[9] Harvard University Center for AIDS Research, Cambridge, MA, USA

[10] Division of General Academic Pediatrics, Massachusetts General Hospital, Boston, MA, USA

[11] Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa

[12] KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

[13] Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

[14] Orthopedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA

[15] Policy and Innovation eValuation in Orthopedic Treatments (PIVOT) Center, Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA

[16] Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA

[17] Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Corresponding Author

Krishna P. Reddy, MD, MS

Medical Practice Evaluation Center

Massachusetts General Hospital

100 Cambridge Street, Suite 1600

Boston, MA 02114

USA

Phone: +1 617-726-1993

Fax: +1 617-726-4120

Email: kpreddy@mgh.harvard.edu

Keywords: COVID-19, cost-effectiveness, resource-limited setting, South Africa, resource allocation

Running title: Cost-effectiveness of COVID-19 interventions in South Africa

Abstract Word Count: 249

Main Text Word Count: 3,497

ABSTRACT

Background

Healthcare resource constraints in low and middle-income countries necessitate selection of cost-effective public health interventions to address COVID-19.

Methods

We developed a dynamic COVID-19 microsimulation model to evaluate clinical and economic outcomes and cost-effectiveness of epidemic control strategies in KwaZulu-Natal, South Africa. Interventions assessed were Healthcare Testing (HT), where diagnostic testing is performed only for those presenting to healthcare centres; Contact Tracing (CT) in households of cases; Isolation Centres (IC), for cases not requiring hospitalisation; community health worker-led Mass Symptom Screening and diagnostic testing for symptomatic individuals (MS); and Quarantine Centres (QC), for contacts who test negative. Given uncertainties about epidemic dynamics in South Africa, we evaluated two main epidemic scenarios over 360 days, with effective reproduction numbers (R_e) of 1·5 and 1·2. We compared *HT*, *HT+CT*, *HT+CT+IC*, *HT+CT+IC+MS*, *HT+CT+IC+QC*, and *HT+CT+IC+MS+QC*, considering strategies with incremental cost-effectiveness ratio (ICER) <US$1,290/year-of-life saved (YLS) to be cost-effective.

Findings

With R_e 1·5, *HT* resulted in the most COVID-19 deaths and lowest costs over 360 days. Compared with *HT*, *HT+CT+IC+MS* reduced mortality by 76%, increased costs by 16%, and was cost-effective (ICER $350/YLS). *HT+CT+IC+MS+QC* provided the greatest reduction in mortality, but increased costs by 95% compared with *HT+CT+IC+MS* and was not cost-effective (ICER $8,000/YLS). With R_e 1·2, *HT+CT+IC+MS* was the least costly strategy, and *HT+CT+IC+MS+QC* was not cost-effective (ICER $294,320/YLS).

Interpretation

In South Africa, a strategy of household contact tracing, isolation, and mass symptom screening would substantially reduce COVID-19 mortality and be cost-effective. Adding quarantine centres for COVID-19 contacts is not cost-effective.

Funding

Royal Society, Wellcome Trust, National Institutes of Health

INTRODUCTION

By early June 2020, 25 countries in sub-Saharan Africa (SSA) had each reported over 1,000 cases of COVID-19.[1] SSA is projected to have a lower infection fatality ratio due to its relatively young population.[2] However, the region may be at risk of severe epidemics due to high urban density, limited opportunities for physical distancing, and poor access to hygiene interventions.[3] The existing public health infrastructure for epidemic response in SSA is also of concern: testing capacity, surveillance infrastructure, isolation facilities, and intensive care (ICU) services are sparse.[4,5]

In the midst of these formidable concerns, low and middle-income countries (LMICs) are implementing epidemic control programs. The World Health Organization (WHO) suggests an array of measures, including disease surveillance platforms, contact tracing, and establishment of isolation facilities.[6] The ability of these measures to limit transmission of communicable diseases has been evaluated in epidemiologic models, which have shown that their efficacy depends on intervention adherence and transmission dynamics.[7,8] Yet few studies have examined these strategies with the consideration of costs, to enable estimation of their cost-effectiveness and feasibility. Limitations in human resources, public health financing, and healthcare facility availability necessitate careful attention to these issues in LMICs.

We used a dynamic microsimulation model to compare medical outcomes and costs for a range of COVID-19 control measures in KwaZulu-Natal, South Africa. Our objective was to inform policy decision making by projecting clinical and economic outcomes, cost-effectiveness, and budget impact of alternative control strategies, focusing on those proposed or currently in use in South Africa.

METHODS

Analytic Overview

We developed the Clinical and Economic Analysis of COVID Interventions (CEACOV) dynamic state-transition Monte Carlo microsimulation model to reflect the natural history, diagnosis, and treatment of COVID-19. We compared six public health intervention strategies (figure S1). Common characteristics of all six strategies are: (a) testing consists of polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on a nasopharyngeal specimen; (b) those awaiting test results are instructed to self-isolate; (c) those who are severely ill (with dyspnoea and/or hypoxemia), regardless of test result, are admitted to a hospital until hospital capacity is reached; (d) those with a negative test result are advised to practice physical distancing and hand hygiene; (e) those with an initial negative test result can present for repeat testing if they develop new or worsening symptoms; (f) those not initially admitted to a hospital can be admitted later if they develop severe illness. Unique characteristics of each modelled strategy are:

1) *Healthcare Testing (HT)*: Approximately 30% of people with mild/moderate COVID-19-like symptoms and all those with severe symptoms self-present to a healthcare centre for testing. Those with a positive test result who are not severely ill are instructed to self-isolate at home.

2) *Contact Tracing (HT+CT)*: In addition to *HT*, household contacts of those with COVID-19 are tested. Those with a positive result are instructed to self-isolate at home.

3) *Contact Tracing + Isolation Centre (HT+CT+IC)*: In addition to *HT+CT*, those who have a positive test result but are not severely ill are referred to an isolation centre (IC)

that offers food, shelter, and basic medical care without supplemental oxygen. They are discharged after 14 days.

4) *Contact Tracing + Isolation Centre + Mass Symptom Screening (HT+CT+IC+MS)*: In addition to *HT+CT+IC*, community healthcare workers conduct screens of the entire population for COVID-19 symptoms once every 6 months and conduct PCR testing for those with symptoms. Those who have a positive PCR result but are not severely ill and cannot safely isolate at home are referred to an IC. As a frame of reference, epidemic control measures in South Africa in June 2020 included combinations of HT, CT, IC, and MS.

5) *Contact Tracing + Isolation Centre + Quarantine Centre (HT+CT+IC+QC)*: In addition to *HT+CT+IC*, household contacts with a negative test result who cannot safely quarantine at home are referred to a quarantine centre (QC) where they receive food and shelter. They are discharged after 14 days, unless they develop COVID-19-like symptoms, in which case they are tested and referred to ICs or hospitals if they test positive, as appropriate.

6) *Contact Tracing + Isolation Centre + Mass Symptom Screening + Quarantine Centre (HT+CT+IC+MS+QC)*: This is a combination of all measures described above.

Starting with SARS-CoV-2 infection prevalence of 0·1%, we modelled COVID-19-specific outcomes over 360 days, including daily and cumulative infections (detected and undetected), deaths, resource utilization, and healthcare costs from the health sector perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER) – the difference in healthcare costs (2019 US dollars [US$]) divided by the difference in life-years – between

intervention strategies over a lifetime horizon, estimating that, on average, 12·9 years of life would be saved from each averted COVID-19 death (appendix). Recognizing no established threshold, we judged an ICER less than $1,290/year-of-life saved (YLS) cost-effective, based on an opportunity cost approach (appendix).[9]

Model Structure

Health States and Natural History

At simulation initiation, each individual is either susceptible to, or infected with, SARS-CoV-2 according to age-stratified probabilities (0-19, 20-59, ≥60 years) (appendix). Once infected, an individual first transitions to the pre-infectious latency state. Each individual faces an age-dependent probability of developing asymptomatic, mild/moderate, severe, or critical disease (appendix, figure S2). Those with critical disease face daily probabilities of death. If they survive, they pass through a recuperation state (remaining infectious) before going to the recovery state. Those in other disease states can transition directly to the recovery state. “Recovered” individuals pose no risk of transmission and are assumed immune from repeat infection for the duration of the simulation. All simulated individuals advance through the model simultaneously to capture infection transmission dynamics.

Transmission

Individuals in asymptomatic, mild/moderate, severe, critical, or recuperation states of COVID-19 may transmit infection to susceptible individuals at state-dependent daily rates. The number of daily infections is a function of the proportion of susceptible people in the population, the distribution of disease states among those with COVID-19, and any interventions that influence transmission (appendix).

Testing and Interventions

For the PCR assay, we defined sensitivity, specificity, time from testing to result, and cost. Each intervention strategy can influence testing probability (e.g., CT and MS), infection transmission rate (e.g., IC and QC), and costs.

Resource Utilization

Individuals with severe or critical disease are referred to hospital and ICU beds, respectively. If those resources are not available at the time, the individual receives the next lower available intervention, which is associated with a different mortality risk and cost (e.g., if a person needs ICU care but there are no ICU beds available, s/he will receive non-ICU hospital care).

Model Calibration

We populated CEACOV with COVID-19 natural history data from published literature (table 1). We used estimates of the basic reproduction number (R_0) and duration of viral shedding in various disease states to calculate transmission rates. We then calibrated the transmission rates to construct an effective reproduction number (R_e) that corresponds to estimates from the South African National Institute for Communicable Diseases in May 2020, after implementation of physical distancing and shelter-in-place policies (appendix).[10]

Input Parameters

Cohort Characteristics

We defined cohort demographic characteristics using the 2019 mid-year population estimates from Statistics South Africa (table 1).[11] Forty-seven percent were aged 0-19 years, 44% were aged 20-59 years, and 9% were aged 60 years or older. Day 0 of the model represents a provincial prevalence of active SARS-CoV-2 infection of 0·1% (approximately 11,000 individuals

with SARS-CoV-2 infection in KwaZulu-Natal), with the remainder of the population susceptible to infection.

Natural History

For those newly infected with SARS-CoV-2, pre-infectious latency was 2·6 days on average. Table 1 indicates the duration of time spent in each state, the probability of developing severe or critical disease, which increased with age, and the age-dependent mortality for those with critical disease.

Transmission

We stratified transmission rates by disease state (table 1). We adjusted transmission rates to reflect an R_e of 1·5.[10] Given uncertainty over values of R_e, both in the past and future, we also simulated scenarios with lower (1·2) and higher (2·6) R_e values (appendix).

Testing and Interventions

In the base case, we assumed a 70% sensitivity, 100% specificity, and five days to PCR result return and action across all active infection states.[12] We defined the probability of undergoing testing based on health state and the intervention strategy in place (table 1). Given limited data about the precise efficacy of each intervention for reducing SARS-CoV-2 transmission rates (e.g., IC), we made assumptions about efficacies and varied them in sensitivity analysis. In the base case, CT and MS increased detection of cases by 17% and 33%, respectively. Ongoing transmission after diagnosis was reduced by 50% from HT alone and by 95% when HT was combined with ICs or QCs (table 1).

Resource Utilization and Costs

The maximum capacity of hospital and ICU beds was 26,220 and 744 per 11 million people, as reported for KwaZulu-Natal by the South African Department of Health (table 1).[13] In the base case, we assumed that IC and QC beds were available to all who needed them. We applied costs of PCR testing, contact tracing, and mass symptom screening, as well as daily costs of hospitalisation, ICU stay, and IC/QC stays based on published estimates and/or cost quotes obtained in KwaZulu-Natal (appendix).

Resource Utilization and Budget Impact Analysis

We conducted resource utilization and budget impact analysis from a health sector perspective for KwaZulu-Natal, South Africa, with a population of 11 million people. We projected the total resources, including testing, hospital/ICU beds, and IC/QC beds, that would be used in each intervention strategy. IC/QC beds are offered to those who meet criteria, and we assumed in the base case that all offered would be used. In budget impact analysis, we projected the total and component healthcare costs associated with each strategy over 360 days and compared them with the 2019 KwaZulu-Natal Department of Health budget of $3·12 billion.[14]

Sensitivity Analysis

We conducted one-way sensitivity analysis by varying key parameters across plausible ranges to determine the impact on clinical and cost projections and policy conclusions (table 1). To extrapolate to other settings, we limited the availability of hospital and ICU beds to the median numbers in countries in SSA (22,275 and 371 per 11 million people).[15] We also examined scenarios with reduced availabilities of IC/QC beds. In multi-way sensitivity analysis, we reduced the efficacies and costs of ICs/QCs to reflect the impact of home-based isolation and quarantine strategies.

RESULTS

Base Case

For an epidemic with R_e=1·5, we projected that *HT* would result in the most COVID-19 infections and deaths, most life-years lost, and lowest costs over 360 days (table 2, figures S3-S4). *HT+CT+IC+MS* provided the greatest clinical benefit while remaining cost-effective (ICER $350/YLS) (figure 1). *HT+CT+IC+MS* decreased life-years lost by 76% and increased costs by 16% compared with *HT*. *HT+CT+IC+MS+QC* yielded the fewest infections, deaths, and life-years lost, but it increased costs by 95% and was not cost-effective (ICER $8,000/YLS) compared with *HT+CT+IC+MS*. *HT+CT+IC* and *HT+CT+IC+QC* resulted in more life-years lost and higher costs compared with alternative strategies.

With R_e=1·2, *HT+CT+IC+MS* was the least costly strategy (table 2). *HT+CT+IC+MS+QC* resulted in fewer life-years lost but increased costs by 6·9-fold compared with *HT+CT+IC+MS*. *HT*, *HT+CT*, *HT+CT+IC*, and *HT+CT+IC+QC* each yielded more life-years lost and higher or similar costs compared with alternative strategies. *HT+CT+IC+MS* in the R_e=1·2 scenario resulted in 94% fewer life-years lost and 75% lower costs compared with *HT+CT+IC+MS* in the R_e=1·5 scenario (table 2, figures S3-S4)

Resource Utilization and Budget Impact Analysis

With R_e=1·5, *HT* resulted in the most cumulative PCR tests performed over 360 days and highest peak daily use of hospital beds (table 3). *HT+CT+IC+MS*, compared with *HT*, reduced cumulative PCR tests performed by 71% and reduced peak daily hospital bed use by 71% (due to fewer cumulative infections), while requiring 19,260 IC beds at peak daily use. Only the *HT+CT+IC+QC* and *HT+CT+IC+MS+QC* strategies maintained peak daily ICU bed demand below capacity, though these strategies required over 100,000 QC beds at peak daily use.

We projected similar patterns for an epidemic with R_e=1·2. *HT+CT+IC+MS*, compared with *HT*, reduced cumulative PCR tests performed by 63% and reduced peak daily hospital bed use by 82%, while requiring 2,080 IC beds at peak daily use. All strategies except *HT* and *HT+CT* maintained peak daily ICU bed demand below capacity.

Over 360 days, for an epidemic with R_e=1·5, PCR testing contributed 6-27% to overall costs in all strategies (figure 2). In strategies with QCs, these centres contributed ≥68% to the overall costs. In strategies without QCs, ICU care was the largest contributor to overall costs, ranging from 51-60%. Costs exclusive of ICU care were $285 million (*HT*), $366 million (*HT+CT+IC+MS*), and $1·329 billion (*HT+CT+IC+MS+QC*), reflecting approximately 9%, 12%, and 43% of the 2019 KwaZulu-Natal Department of Health budget. In relevant strategies, CT and MS together contributed <3% and ICs contributed <24% to overall costs. For an epidemic with R_e=1·2, costs exclusive of ICU care were $196 million (*HT*), $116 million (*HT+CT+IC+MS*), and $1·273 billion (*HT+CT+IC+MS+QC*), reflecting 6%, 4%, and 41% of the 2019 Department of Health budget.

Sensitivity Analysis

The patterns of results were similar to the base case in sensitivity analyses for: the costs of CT and MS (table S1) and hospitalisation (table S2); PCR sensitivity and time to result (table S3) and PCR cost (table S4); and availability of IC and QC beds (table S5) and hospital and ICU beds (table S6). *HT+CT+IC+MS* remained cost-effective, while *HT+CT+IC+MS+QC* provided the greatest clinical benefit but at much higher cost that resulted in an ICER above the cost-effectiveness threshold.

Conversely, our projected ICERs changed meaningfully in a model with an R_e of 2·6 – resource requirements increased substantially, making *HT+CT+IC+MS* no longer cost-effective (ICER

$6,810/YLS), and *HT+CT* became the cost-effective strategy (ICER $1,000/YLS) (table S7). Similarly, when the efficacies of CT and MS to detect infections were halved from the base case values, *HT+CT+IC+MS* was no longer cost-effective (ICER $4,340/YLS) (table S8). When the efficacy of ICs for transmission reduction was decreased from 95% to 75%, the ICER of *HT+CT+IC+MS* ($1,990/YLS) was above the cost-effectiveness threshold (table S9). When the IC/QC costs decreased, *HT+CT+IC+MS+QC* became more favourable in terms of cost-effectiveness (table S10).

In a multi-way sensitivity analysis that reduced efficacies and costs of IC/QC strategies to assess lower-cost but potentially lower-efficacy home-based IC and QC programs, *HT+CT+IC+MS* remained cost-effective in most scenarios, including all scenarios in which transmission reduction remained ≥85% and costs were ≥50% of base case costs (figure S5). *HT+CT+IC+MS+QC* resulted in fewer life-years lost and lower costs than *HT+CT+IC+MS* when transmission reduction remained at 95% and QC costs were 25% of base case values.

DISCUSSION

A public health strategy combining contact tracing, isolation of those with confirmed COVID-19, and community-based mass symptom screening will substantially reduce infections, hospitalisations, and deaths and is an efficient use of healthcare resources in KwaZulu-Natal, South Africa. We estimate that this strategy would cost an additional $350 per YLS, which compares favourably with the cost-effectiveness of many established public health interventions in South Africa, including tuberculosis diagnostic testing[16] and cervical cancer screening.[17] In a scenario of lower epidemic growth, this package of COVID-19 interventions was even more attractive due to earlier containment and prevention of downstream infections, yielding cost savings over 360 days. Although our projections suggest that quarantine centres for contacts who test negative will reduce infections and deaths further, this would require a substantial financial investment that does not meet standard cost-effective thresholds and may be unaffordable.

Our results are robust to most sensitivity analyses, reflecting generalizability to settings with resource constraints, to epidemics at varying degrees of acceleration (in line with published estimates in South Africa[10,18]) – with and without physical distancing measures in place – and with varying costs of interventions.[19] *HT+CT+IC+MS* generally remained cost-effective throughout most of these scenarios. A notable exception was when R_e was 2·6, when the epidemic outpaced the ability of these control measures, and costs increased substantially.

Our model parameters and specifications were selected for their relevance to LMICs. Our estimates are based on the population structure of KwaZulu-Natal, South Africa, with a median age of 27 years (compared with 38 years in the USA), and thus are likely to reflect epidemic scenarios in LMICs with similarly young age structures. We also chose intervention scenarios based on prior work supporting their efficacy for epidemic control, WHO recommendations, and

particular relevance to settings with limitations in formal healthcare infrastructure.[6–8] For example, we specified our model to reflect the number of available hospital and ICU beds in KwaZulu-Natal,[13] and results were similar when we further restricted bed availability to that elsewhere in SSA.[15] Contact tracing and community-based screening campaigns have been frequently used for case-finding in LMICs.[20] Many countries in SSA are thus theoretically poised to implement such interventions through established networks of community health workers or volunteers. Finally, isolation centres, which are likely to require the greatest investment in new infrastructure, have been implemented successfully in response to Ebola epidemics in West Africa and the Democratic Republic of Congo, where healthcare resources are among the lowest in the world.[21]

Isolation centres in our model are designed as housing facilities for people with confirmed COVID-19 who do not require hospital-level care but cannot safely isolate at home. We estimated that their use reduces ongoing transmission after a confirmed diagnosis from 50% (in the *HT* strategy) to 5%. They are likely to be most effective in areas with high population and household density and limited capacity for in-home isolation, as is the case for many urban centres in SSA. Quarantine centres, which include optional housing for contacts who test negative and cannot safely distance during the latency period, have also been proposed for interrupting epidemic spread and were implemented in the early phases of the COVID-19 response in China. They were also effective in our model at reducing the deleterious impact of the epidemic, but at a high financial cost to the health sector. At a cost of $8,000/YLS, these quarantine centres are unlikely to be cost-effective in most publicly funded healthcare systems in LMICs.

Importantly, there are critical social and human rights considerations to implementation of both isolation and quarantine in many settings, due to trade-offs between public health benefits and

civil liberties.[22] In our model, both interventions are provided optionally for those who cannot do so safely at home, but we conservatively included costs to reflect needs should they be used. We also considered the use of home-based isolation and quarantine in a multi-way analysis that reduced efficacies and costs of both. We found that isolation remained cost-effective even in lower efficacy scenarios, but that quarantine was cost-effective only if efficacy remained extremely high (95% reduction in transmission) and costs were reduced to 25% of the base case values. On balance, our findings do not support use of quarantine centres in areas without significant resources, public support for their use, or an intervention design that allows high efficacy with minimal costs.

Our model should be interpreted within the context of several limitations. We did not account for heterogenous mixing within the population. Instead, we assumed that contact patterns were random, as is commonly done in infectious disease models. We assumed that age is the primary determinant of COVID-19 disease progression as demonstrated in multiple settings.[23,24] We did not specify prevalence of co-morbidities or their age-independent effect on COVID-19 outcomes. Currently, there are limited data about a modifying effect of HIV on the severity of COVID-19.[25] In the absence of data, we assumed that risks of COVID-19 and outcomes for people with HIV are similar to those of others in their age group. It will be crucial to consider how resources and interventions implemented in response to COVID-19 stand to impact available resources for other regional healthcare priorities. In our projections of lifetime ICER, we did not include lifetime costs of healthcare beyond COVID-19, but prior studies have estimated expenditures of South Africa's healthcare sector to be approximately $600 annually per capita, not including HIV care costs.[26] As with all modelling exercises, our estimates are determined by assumptions of input parameters. We selected COVID-19 clinical parameters based on the published literature, which are largely derived from high-income settings. Intervention efficacy estimates were hypothesized based on other model parameters, existing

literature where available, or expert opinion if no data were available. Recognizing a lack of empiric data for some of these estimates, we focused our sensitivity analyses on varying these estimates to assess their influence on the results. Finally, costing data were derived from the literature and direct cost estimates from local suppliers in KwaZulu-Natal and therefore might not reflect costs in other contexts. Nonetheless, our primary findings and policy conclusions were largely consistent across a range of costing estimates.

We report results from a model-based cost-effectiveness analysis, demonstrating that a combination of contact tracing, isolation of those with confirmed COVID-19, and mass symptom screening is likely to limit the size of the COVID-19 epidemic in South Africa and would be cost-effective from a healthcare sector perspective. We recommend that policymakers consider this combination of interventions to address COVID-19 epidemic control efficiently.

AUTHOR ROLES

All authors contributed substantively to this manuscript in the following ways: study and model design (all authors), data analysis (KPR, FMS, JHAF, GH, KAF, PK, MJS), interpretation of results (all authors), drafting the manuscript (KPR, MJS), critical revision of the manuscript (all authors) and final approval of submitted version (all authors).

CONFLICTS OF INTEREST AND FINANCIAL DISCLOSURES

The authors have no conflicts of interest or financial disclosures.

FUNDING

This work was supported by a fellowship from the Royal Society and Wellcome Trust [210479/Z/18/Z] and by the National Institutes of Health [K24 AR057827 and T32 AI007433].

The funding sources had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources.

REFERENCES

1. Xu B, Kraemer MUG, Xu B, Gutierrez B, Mekaru S, Sewalk K, et al. Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis. 2020 May;20(5):534.
2. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020 Jun;S2214109X20302643.
3. Johnstone-Robertson SP, Mark D, Morrow C, Middelkoop K, Chiswell M, Aquino LDH, et al. Social mixing patterns within a South African township community: implications for respiratory disease transmission and control. Am J Epidemiol. 2011 Dec 1;174(11):1246–55.
4. Siedner MJ, Gostin LO, Cranmer HH, Kraemer JD. Strengthening the detection of and early response to public health emergencies: lessons from the West African Ebola epidemic. PLoS Med. 2015 Mar;12(3):e1001804.
5. Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle P-Y, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. 2020 Mar;395(10227):871–7.
6. World Health Organization. COVID-19 Strategic Preparedness and Response Plan: Operational planning guidelines to support country preparedness and response [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://www.who.int/docs/default-source/coronaviruse/covid-19-sprp-unct-guidelines.pdf?sfvrsn=81ff43d8_4
7. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health. 2020 Apr;8(4):e488–96.
8. Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci. 2017 Apr 11;114(15):4023–8.

9. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016 Dec;19(8):929–35.
10. National Institute for Communicable Diseases. The Initial and Daily COVID-19 Effective Reproductive Number (R) in South Africa [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://www.nicd.ac.za/wp-content/uploads/2020/05/The-Initial-and-Daily-COVID-19-Effective-Reproductive-Number-R-in-South-Africa-002.pdf
11. Statistics South Africa. Mid-year population estimates [Internet]. 2020 [cited 2020 Jun 24]. Available from: http://www.statssa.gov.za/?s=mid-year+population+estimates&sitem=publications
12. National Institute for Communicable Diseases. COVID-19 Testing Summary [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://www.nicd.ac.za/wp-content/uploads/2020/05/NICD-COVID-19-Testing-Summary_-Week-21-2020-007.pdf
13. National Department of Health, South Africa. COVID-19 Public Health Response [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://sacoronavirus.co.za/2020/04/11/covid-19-public-health-response/
14. Province of KwaZulu-Natal, Department of Health. Annual Performance Plan 2019/20-2021/22 [Internet]. 2019 [cited 2020 Jun 24]. Available from: http://www.kznhealth.gov.za/app/APP-2019-20.pdf
15. Craig J, Kalanxhi E, Hauck S. National estimates of critical care capacity in 54 African countries. [Internet]. Public and Global Health; 2020 Jun [cited 2020 Jun 22]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.05.13.20100727
16. Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, et al. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Glob Health. 2019 Feb;7(2):e200–8.

17. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005 Nov 17;353(20):2158–68.
18. Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine. COVID-19 Estimates for South Africa [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://epiforecasts.io/covid/posts/national/south-africa/
19. Siedner MJ, Harling G, Reynolds Z, Gilbert RF, Venkataramani A, Tsai AC. Social distancing to slow the U.S. COVID-19 epidemic: an interrupted time-series analysis [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jun [cited 2020 Jun 24]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.03.20052373
20. Shapiro AE, Variava E, Rakgokong MH, Moodley N, Luke B, Salimi S, et al. Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med. 2012 May 15;185(10):1110–6.
21. Legrand J, Grais RF, Boelle PY, Valleron AJ, Flahault A. Understanding the dynamics of Ebola epidemics. Epidemiol Infect. 2007 May;135(4):610–21.
22. Blendon RJ, Koonin LM, Benson JM, Cetron MS, Pollard WE, Mitchell EW, et al. Public response to community mitigation measures for pandemic influenza. Emerg Infect Dis. 2008 May;14(5):778–86.
23. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020 May 22;m1923.
24. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.

25. Karmen-Tuohy S, Carlucci PM, Zacharioudakis IM, Zervou FN, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19 [Internet]. HIV/AIDS; 2020 May [cited 2020 Jun 10]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.05.07.20094797
26. Dieleman JL, Haakenstad A, Micah A, Moses M, Abbafati C, Acharya P, et al. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015. Lancet. 2018 May;391(10132):1799–829.
27. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Feb [cited 2020 Jun 10]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.11.20021493
28. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020 Mar 11;323(18):1843–4.
29. Netcare Hospitals. Netcare Tariffs [Internet]. 2016 [cited 2020 Jun 10]. Available from: https://www.netcarehospitals.co.za/
30. Mahomed S, Mahomed OH. Cost of intensive care services at a central hospital in South Africa. S Afr Med J. 2018 Dec 13;109(1):35.

TABLES

Table 1. Input parameters for a model-based analysis of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

Parameter	Value (Range)				Source
Cohort Characteristics					
Age distribution, %					[11]
0-19y	47				
20-59y	44				
≥60y	9				
Natural History					
Proportion in each health state at model start, %					Asm.
Susceptible	99·900				
Infected					
Pre-infectious latency	0·030				
Asymptomatic	0·030				
Mild/moderate disease	0·030				
Severe disease	0·005				
Critical disease	0·005				
Recuperation after critical disease	0·000				
Recovered	0·000				
Disease path probability*, stratified by age, %	Asymp.	Mild/Mod.	Severe	Critical	See Appendix
0-19y	52·39	47·10	0·50	0·01	
20-59y	26·20	71·95	1·18	0·67	
≥60y	18·00	78·79	0·09	3·12	
Duration of health states, stratified by disease path, days	Asymp.	Mild/Mod.	Severe	Critical	See Appendix
Pre-infectious latency	2·6	2·6	2·6	2·6	
Asymptomatic	9·5	2·0	2·0	2·0	
Mild/moderate disease	--	10·0	6·5	3·0	
Severe disease	--	--	10·5	7·1	
Critical disease	--	--	--	11·9	
Recuperation after critical disease	--	--	--	5·7	

560 **Table 1, continued.**

Parameter	Value (Range)			Source
Natural History, continued				
Mortality probability among those with critical COVID-19 disease, stratified by age, daily, %	0-19y	20-59y	≥60y	See Appendix
Without hospital care	11·7500	16·6200	20·3300	
With hospital care	0·0006	3·8000	5·0000	
Transmission				
Probability of onward transmission, daily, stratified by health state				See Appendix
Asymptomatic		0·2394		
Mild/moderate disease		0·1948		
Severe disease		0·0135		
Critical disease		0·0107		
Recuperation after critical disease		0·0135		
Effective reproductive number (R_e, range)		1·5 (1·2-2·6)		[10]
PCR Testing				
Sensitivity†, nasopharyngeal specimen, % (range)		70 (50-90)		[27,28]
Specificity, nasopharyngeal specimen, %		100		Asm.
Cost, 2019 US$ (range)		26 (13-52)		AHRI
Time to result return and action, days (range)		5 (1-7)		AHRI
Resource Utilization				
Resources available per 11,000,000 people, n				
Hospital beds		26,220		[13]
ICU beds		744		[13]
Isolation centre beds		As needed, no capacity limitation		Asm.
Quarantine centre beds		As needed, no capacity limitation		Asm.
Cost, per person, 2019 US$ (range)				
Hospital bed, daily		165 (83-330)		[29]
ICU bed, daily		2,059 (1,030-4,118)		[30]
Contact tracing/mass symptom screen, per instance		3 (2-6)		AHRI
Isolation centre bed, daily		44 (22-88)		AHRI
Quarantine centre bed, daily		37 (19-74)		AHRI

Table 1, continued.

Parameter	Value (Range)						Source
Intervention Strategies	***HT***	***HT+CT***	***HT+CT +IC***	***HT+CT +IC+MS***	***HT+CT +IC+QC***	***HT+CT +IC+MS+QC***	
Cumulative probability of undergoing testing, over health state duration, %							Asm.
Susceptible	0	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	1 (1-2)	
Pre-infectious latency	0	10 (5-20)	10 (5-20)	10 (5-20)	10 (5-20)	10 (5-20)	
Asymptomatic	0	10 (5-20)	10 (5-20)	10 (5-20)	10 (5-20)	10 (5-20)	
Mild/moderate disease	30	35 (33-40)	35 (33-40)	40 (35-50)	35 (33-40)	40 (35-50)	
Severe disease	100	100	100	100	100	100	
Critical disease	100	100	100	100	100	100	
Reduction in onward transmission, % (range)							
Home isolation/quarantine	50 (25-75)	50 (25-75)	50 (25-75)	50 (25-75)	--	--	Asm.
Isolation centre	--	--	95 (75-99)	95 (75-99)	95 (75-99)	95 (75-99)	Asm.
Quarantine centre	--	--	--	--	95 (75-99)	95 (75-99)	Asm.

COVID-19: coronavirus disease 2019. y: years. Asm.: assumption. Mod.: moderate. PCR: polymerase chain reaction. US$: United States dollars. ICU: intensive care unit. AHRI: Africa Health Research Institute (KwaZulu-Natal, South Africa; personal communication). HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Ranges, in parentheses, are those evaluated in sensitivity analysis.

*Disease path probability refers to the likelihood that an individual, once infected with SARS-CoV-2, will eventually progress to the specified COVID-19 disease state.

573 [†]Test sensitivity does not vary by disease stage, except that is 0% in the pre-infectious latency phase.

Table 2. Model-projected life-years lost, healthcare costs, and cost-effectiveness of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

Effective reproduction number (R_e)	Strategy	Total life-years lost,* n	Healthcare costs over 360 days, US$†	ICER, US$/YLS‡
1·5	*HT*	487,290	668,000,000	--
	HT+CT	320,760	704,000,000	220
	HT+CT+IC+MS	116,220	776,000,000	350
	HT+CT+IC	152,760	798,000,000	dominated
	HT+CT+IC+MS+QC	24,340	1,511,000,000	8,000
	HT+CT+IC+QC	32,070	1,569,000,000	dominated
1·2	*HT+CT+IC+MS*	7,100	190,000,000	--
	HT+CT+IC	14,190	238,000,000	dominated
	HT+CT	55,480	502,000,000	dominated
	HT	268,900	625,000,000	dominated
	HT+CT+IC+MS+QC	3,260	1,318,000,000	294,320
	HT+CT+IC+QC	4,830	1,318,000,000	dominated

COVID-19: coronavirus disease 2019. ICU: intensive care unit. US$: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. dominated: associated with more life-years lost and higher costs than another strategy.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis. The cost-effective strategy, *HT+CT+IC+MS*, is highlighted in light grey in each R_e scenario.

*We assumed that each death results in 12·9 life-years lost, on average, based on our derivation (appendix).

†This reflects costs to the healthcare sector.

‡The ICER is the difference between two strategies in costs divided by the difference in life-years. We considered a strategy cost-effective if its ICER was less than US$1,290/YLS.[9]

Table 3. Model-projected resource utilization of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

Effective reproduction number (R_e)	Strategy	Cumulative PCR tests performed over 360 days, n	Peak daily resource use, n				
			PCR tests	Hospital beds (non-ICU)	ICU beds*	Isolation centre beds	Quarantine centre beds
1·5	*HT*	6,797,070	62,810	5,610	744	--	--
	HT+CT	6,461,580	35,920	3,670	744	--	--
	HT+CT+IC+MS	4,867,750	18,210	1,620	744	19,260	--
	HT+CT+IC	4,955,220	20,100	2,020	744	21,860	--
	HT+CT+IC+MS+QC	3,388,490	11,270	450	440	11,450	102,710
	HT+CT+IC+QC	3,376,070	11,230	680	545	15,310	103,150
1·2	*HT+CT+IC+MS*	3,000,180	10,410	480	530	2,080	--
	HT+CT+IC	3,001,420	10,790	530	530	2,660	--
	HT+CT	3,924,440	13,350	1,060	744	--	--
	HT	4,612,870	28,110	2,700	744	--	--
	HT+CT+IC+MS+QC	2,846,140	10,410	470	530	1,540	104,120
	HT+CT+IC+QC	2,648,640	9,790	480	530	1,680	105,710

COVID-19: coronavirus disease 2019. PCR: polymerase chain reaction. ICU: intensive care unit. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Strategies are listed in order of ascending costs as indicated in table 2, per convention of cost-effectiveness analysis. The cost-effective strategy, *HT+CT+IC+MS*, is highlighted in light grey in each R_e scenario.

*The total number of available ICU beds was 744.

FIGURE LEGENDS

Figure 1. Cost-effectiveness efficiency frontier: COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

COVID-19: coronavirus disease 2019. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Model results are shown for an effective reproduction number of 1·5. Strategies that are below the line are dominated – i.e. an inefficient use of resources compared with other strategies. For all other strategies, ICERs are shown below the strategy label.

Figure 2. Budget impact analysis: contributors to healthcare costs of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. COVID-19: coronavirus disease 2019. R_e: effective reproduction number. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Panel A shows results for an epidemic with R_e=1·5, and Panel B shows results for an epidemic with R_e=1·2. The figures show the total and component COVID-19-related healthcare costs, from a health sector perspective, associated with different intervention strategies when applied to the entire KwaZulu-Natal population of 11 million people. The costs are derived from model-generated results. Percentages in parentheses represent the proportion of the 2019 KwaZulu-Natal Department of Health budget.

FIGURES

Figure 1.



Figure 2.


(A) R_e = 1·5
Total healthcare costs at 360 days, US$, millions
1,800
1,600
1,400
1,200
1,000
800
600
400
200
0
668 (21%)
704 (23%)
776 (25%)
798 (26%)
1,511 (48%)
1,569 (50%)
HT
HT+CT
HT+CT+IC+MS
HT+CT+IC
HT+CT+IC+MS+QC
HT+CT+IC+MS+QC
Strategy
Quarantine Center Care
Isolation Center Care
Contact Tracing + Mass Symptom Screening
ICU Care
Hospital Care (non-ICU)
PCR Testing
(B) R_e = 1·2
Total healthcare costs at 360 days, US$, millions
1,800
1,600
1,400
1,200
1,000
800
600
400
200
0
190 (6%)
238 (8%)
502 (16%)
625 (20%)
1,318 (42%)
1,318 (42%)
HT+CT+IC+MS
HT+CT+IC
HT+CT
HT
HT+CT+IC+MS+QC
HT+CT+IC+QC
Strategy